Hepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment
Open Access
- 13 April 2026
- journal article
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (2) , 385-389
Abstract
Purpose: Hepatitis A is a vaccine-preventable disease that may follow a more severe course and can lead to fulminant hepatitis in patients with chronic hepatitis. The aim of this study is to determine the seroprevalence of hepatitis A in patients with chronic hepatitis B and C, and to assess the need for hepatitis A vaccination.Materials and methods: A total of 885 adult patients with chronic hepatitis B and C, who had not previously received hepatitis A vaccination and in whom antiviral therapy was initiated between January 2008 and December 2020, were included in the study. Immunity against hepatitis A was assessed at the time of diagnosis by measuring Anti-HAV IgG using the Microparticle Enzyme Immunoassay (MEIA; AxSYM-HAVAB 2.0, ABBOTT) method.Results: The seroprevalence of hepatitis A was 92.7% among 789 patients with chronic hepatitis B and 96 patients with chronic hepatitis C; it was determined to be 94% in patients with chronic hepatitis B and 83% in patients with chronic hepatitis C. While 78% of anti-HAV IgG seronegativity was detected in individuals under 30 years of age, 90% of seronegative cases were under 40. Seropositivity approached 100% in those over 50 years of age; however, a 64-year-old man and a 68-year-old woman with chronic hepatitis C were not immune to hepatitis A.Conclusion: Since hepatitis A superinfection in patients with chronic hepatitis B and C may follow a severe course and lead to a fulminant course, it should be kept in mind that hepatitis A seroprevalence is low, particularly in patients under 30 years of age. However, although the rate decreases with age in adult patients, seronegativity may be detected at any age; therefore, Anti-HAV IgG should be evaluated at the time of diagnosis in all patients with chronic hepatitis, and those found to be negative should be vaccinated against hepatitis A.Keywords
This publication has 10 references indexed in Scilit:
- Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020MMWR. Recommendations and Reports, 2020
- Hepatitis A Seroprevalence in Chronic Hepatitis B Patients in Diyarbakir, TurkeyKlimik Dergisi/Klimik Journal, 2020
- Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus InfectionKlimik Dergisi/Klimik Journal, 2019
- Hepatitis A virus epidemiology in Turkey as universal childhood vaccination begins: seroprevalence and endemicity by regionThe Turkish Journal of Pediatrics, 2016
- Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, TurkeyEuropean Journal of Gastroenterology & Hepatology, 2016
- Hepatitis A seroprevalence in children and adolescents aged 1–18 years among a low socioeconomic population in Izmir, TurkeyTravel Medicine and Infectious Disease, 2012
- Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendationsJournal of Viral Hepatitis, 2008
- Hepatitis vaccination in patients with chronic liver diseaseAlimentary Pharmacology & Therapeutics, 2004
- Immunogenicity of Hepatitis A Vaccination in Decompensated Cirrhotic PatientsHepatology, 2001
- Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver diseaseHepatology, 1998